BRIEF published on 01/01/2026 at 07:35, 10 months 16 days ago Evotec Appoints Dr. Sarah Fakih as EVP of Global Communications and Investor Relations Investor Relations Leadership Communications Evotec Sarah Fakih
PRESS RELEASE published on 01/01/2026 at 07:30, 10 months 16 days ago Evotec appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations Evotec appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations to strengthen strategic messaging and stakeholder alignment Investor Relations Appointment Evotec Global Communications Dr. Sarah Fakih
BRIEF published on 12/08/2025 at 07:05, 11 months 9 days ago Evotec finalise la vente de son site de Toulouse à Sandoz pour 350 millions de dollars. Croissance Des Revenus Licence Technologique Evotec Biosimilaires Sandoz
BRIEF published on 12/08/2025 at 07:05, 11 months 9 days ago Evotec Finalizes Sale of Toulouse Site to Sandoz for $350 Million Revenue Growth Biosimilars Evotec Sandoz Technology License
PRESS RELEASE published on 12/08/2025 at 07:00, 11 months 9 days ago Evotec closes sale of Just – Evotec Biologics’ Toulouse site to Sandoz Evotec closes sale of Just - Evotec Biologics' Toulouse site to Sandoz for over US$650m, including technology license fees. Sale improves revenue mix and profit margins Technology Sale Evotec Sandoz Biologics
BRIEF published on 12/04/2025 at 08:35, 11 months 13 days ago Bayer Initiates Phase 2 Study for Alport Syndrome Treatment with Evotec Clinical Trial Bayer Evotec Alport Syndrome Semaphorin-3A
BRIEF published on 12/04/2025 at 08:35, 11 months 13 days ago Bayer lance une étude de phase 2 pour le traitement du syndrome d'Alport avec Evotec Bayer Essai Clinique Evotec Syndrome D'Alport Sémaphorine-3A
PRESS RELEASE published on 12/04/2025 at 08:30, 11 months 13 days ago Evotec-partner Bayer starts Phase 2 study for treatment of patients with Alport syndrome Evotec-partner Bayer initiates Phase 2 study for potential Alport syndrome treatment. BAY 3401016 mAb targets Sema3A protein Bayer Evotec Phase 2 Study Alport Syndrome BAY 3401016
BRIEF published on 11/12/2025 at 07:35, 1 year ago Evotec Secures Milestone Payment from Bristol Myers Squibb FDA Approval Evotec Milestone Payment Bristol Myers Squibb Protein Degradation
BRIEF published on 11/12/2025 at 07:35, 1 year ago Evotec obtient un paiement d'étape de Bristol Myers Squibb Evotec Approbation De La FDA Paiement D'étape Bristol Myers Squibb Dégradation Des Protéines
Published on 11/18/2026 at 00:35, 3 hours 44 minutes ago Route1 Appoints Tom Park to Board of Directors and Announces Board Changes
Published on 11/17/2026 at 23:40, 4 hours 39 minutes ago AI/ML Innovations Inc. Closes First Tranche of Private Placement
Published on 11/17/2026 at 23:00, 5 hours 19 minutes ago Alset AI Ventures Inc. Announces Extension of Annual General Meeting Deadline
Published on 11/17/2026 at 21:30, 6 hours 49 minutes ago Fairplay Ventures INC. Announces Filing of Filing Statement in Connection With Qualifying Transaction
Published on 11/17/2026 at 15:00, 13 hours 19 minutes ago Secure Blockchain's Agentic Solutions Signs Engineering Company, Expanding Enterprise AI Into Heavy Industry
Published on 11/18/2026 at 03:15, 1 hour 4 minutes ago China’s Recombinant Collagen Technology Wins the INPD Innovative Manufacturing Process Award
Published on 11/18/2026 at 03:15, 1 hour 4 minutes ago La technologie chinoise du collagène recombinant remporte le prix INPD du procédé de fabrication innovant
Published on 11/18/2026 at 01:55, 2 hours 24 minutes ago WIRobotics and Ottobock Join Forces to Expand Access to Wearable Robots Across North America
Published on 11/18/2026 at 01:40, 2 hours 39 minutes ago AMPERA and Berto Announce Proposed Business Combination to Accelerate Advanced Energy Technology Development and Commercialization
Published on 11/18/2026 at 00:59, 3 hours 20 minutes ago Linedata Services: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Published on 11/17/2026 at 18:00, 10 hours 19 minutes ago 20261117 - Accor - Accor to increase its stake in Ennismore
Published on 11/17/2026 at 18:00, 10 hours 19 minutes ago Accor - Accor se renforce au capital de Ennismore
Published on 11/17/2026 at 17:45, 10 hours 34 minutes ago EURAZEO COMPLETES THE SALE OF ITS STAKE IN AROMA-ZONE AND ITS REINVESTMENT ALONGSIDE PARTNERS GROUP
Published on 11/17/2026 at 17:45, 10 hours 34 minutes ago EURAZEO FINALISE LA CESSION DE SA PARTICIPATION DANS AROMA-ZONE ET SON REINVESTISSEMENT AUX COTES DE PARTNERS GROUP
Published on 11/17/2026 at 07:40, 20 hours 39 minutes ago SUEZ INTERNATIONAL SAS COMPLETES THE SALE OF C.10.65 MILLION SHARES OF ACEA S.P.A.